YAP1 and cancer: YAP depletion further sensitizes human cancer cells to anti-cancer agents, such as cisplatin or the EGFR tyrosine kinase inhibitor erlotinib[118], and increased YAP/TAZ levels correlate with taxol and cisplatin resistance[100,119,120].